BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 254 filers reported holding BRIDGEBIO PHARMA INC in Q4 2023. The put-call ratio across all filers is 1.26 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $12,620,774 | -18.4% | 498,254 | -0.4% | 0.66% | -17.9% |
| Q1 2024 | $15,467,854 | -23.4% | 500,254 | 0.0% | 0.80% | -24.7% |
| Q4 2023 | $20,195,254 | +53.1% | 500,254 | 0.0% | 1.07% | +34.3% |
| Q3 2023 | $13,191,698 | +93.9% | 500,254 | +26.5% | 0.80% | +115.7% |
| Q2 2023 | $6,803,288 | – | 395,540 | – | 0.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $60,317,000 | 40.05% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $308,746,000 | 6.20% |
| M28 Capital Management LP | 513,300 | $5,102,000 | 5.33% |
| GREAT POINT PARTNERS LLC | 1,050,000 | $10,437,000 | 2.51% |
| Octagon Capital Advisors LP | 933,743 | $9,281,000 | 1.60% |
| HHLR ADVISORS, LTD. | 5,362,014 | $53,298,000 | 1.40% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $264,613,000 | 1.22% |
| Cormorant Asset Management, LP | 1,469,179 | $14,604,000 | 1.02% |
| Fernwood Investment Management, LLC | 204,550 | $2,033,000 | 0.86% |
| TANG CAPITAL MANAGEMENT LLC | 585,424 | $5,819,000 | 0.71% |